Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Harten, Sarah K ^a,c   Esteban, Miguel A ^b   Shukla, Deepa ^a   Ashcroft, Margaret ^a   Maxwell, Patrick H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLOXALYLGLYCINE; GLYCINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NEUROMEDIN U; NEUROMEDIN U RECEPTOR; RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; HIF1A PROTEIN, HUMAN; NEUROPEPTIDE; VHL PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL HYPOXIA; CELL MIGRATION; GENE EXPRESSION; GENE INACTIVATION; KIDNEY CARCINOMA; MICROARRAY ANALYSIS; UPREGULATION; DRUG ANTAGONISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

PYRONIA TITHONUS;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MICROARRAY ANALYSIS; NEUROPEPTIDES; UP-REGULATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79960679773     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-89     Document Type: Article

References (28)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132. 10.1016/S0140-6736(09)60229-4, 19269025.
2. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002, 2:673-682. 10.1038/nrc885, 12209156.
3. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Hui Wei M, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DR, Dean M, Glavačc D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320. 10.1126/science.8493574, 8493574.
4. Harten SK, Esteban MA, Maxwell PH. Identification of novel VHL regulated genes by transcriptomic analysis of RCC10 renal carcinoma cells. Adv Enzyme Regul 2009, 49:43-52. 10.1016/j.advenzreg.2008.12.005, 19162062.
5. Calzada MJ, Esteban MA, Feijoo-Cuaresma M, Castellanos MC, Naranjo-Suarez S, Temes E, Mendez F, Yanez-Mo M, Ohh M, Landazuri MO. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res 2006, 66:1553-1560. 10.1158/0008-5472.CAN-05-3236, 16452212.
6. Harten SK, Deepa S, Barod R, Hergovich A, Balda M, Matter K, Esteban MA, Maxwell PH. Regulation of renal epithelial tight junctions by the VHL tumor suppressor gene involves repression of occludin and claudin 1 and is independent of E-cadherin. Mol Biol Cell 2009, 20:13.
7. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, Raval R, O'Brien T S, Maxwell PH. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006, 66:3567-3575. 10.1158/0008-5472.CAN-05-2670, 16585181.
8. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, Semenza GL. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 2006, 66:2725-2731. 10.1158/0008-5472.CAN-05-3719, 16510593.
9. Esteban MA, Harten SK, Tran MG, Maxwell PH. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J Am Soc Nephrol 2006, 17:1801-1806. 10.1681/ASN.2006020181, 16775032.
10. Thoma CR, Frew IJ, Hoerner CR, Montani M, Moch H, Krek W. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol 2007, 9:588-595. 10.1038/ncb1579, 17450132.
11. Lutz MS, Burk RD. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells. Cancer Res 2006, 66:6903-6907. 10.1158/0008-5472.CAN-06-0501, 16849532.
12. Brighton PJ, Szekeres PG, Willars GB. Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol Rev 2004, 56:231-248. 10.1124/pr.56.2.3, 15169928.
13. Shetzline SE, Rallapalli R, Dowd KJ, Zou S, Nakata Y, Swider CR, Kalota A, Choi JK, Gewirtz AM. Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 2004, 104:1833-1840. 10.1182/blood-2003-10-3577, 15187020.
14. Ketterer K, Kong B, Frank D, Giese NA, Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW, Friess H. Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett 2009, 277:72-81. 10.1016/j.canlet.2008.11.028, 19118941.
15. Hanada R, Teranishi H, Pearson JT, Kurokawa M, Hosoda H, Fukushima N, Fukue Y, Serino R, Fujihara H, Ueta Y, Ikawa M, Okabe M, Murakami N, Shirai M, Yoshimatsu H, Kangawa K, Kojima M. Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat Med 2004, 10:1067-1073. 10.1038/nm1106, 15448684.
16. Minamino N, Kangawa K, Matsuo H. Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. Biochem Biophys Res Commun 1985, 130:1078-1085. 10.1016/0006-291X(85)91726-7, 3839674.
17. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275. 10.1038/20459, 10353251.
18. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634.
19. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995, 269:1444-1446. 10.1126/science.7660130, 7660130.
20. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001, 10:1019-1027. 10.1093/hmg/10.10.1019, 11331612.
21. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992, 12:5447-5454. 360482, 1448077.
22. Wu Y, McRoberts K, Berr SS, Frierson HF, Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2007, 26:765-773. 10.1038/sj.onc.1209835, 16878152.
23. Takahashi K, Furukawa C, Takano A, Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, Sone S, Ito T, Nishimura H, Tsuchiya E, Nakamura Y, Daigo Y. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006, 66:9408-9419. 10.1158/0008-5472.CAN-06-1349, 17018595.
24. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007, 13:4740-4749. 10.1158/1078-0432.CCR-07-0143, 17699851.
25. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009, 69:4674-4681. 10.1158/0008-5472.CAN-09-0146, 2745239, 19470766.
26. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005, 11:5730-5739. 10.1158/1078-0432.CCR-04-2225, 16115910.
27. Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells. Int J Mol Med 2007, 20:605-611.
28. Euer NI, Kaul S, Deissler H, Mobus VJ, Zeillinger R, Weidle UH. Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep 2005, 13:375-387.